Using these small-molecule inhibitors, we show that direct pharmacologic inhibition of KRAS in the inactive “OFF” state results in growth inhibition in KRAS WT–amplified cancer cell lines in vitro and in CDX and PDX models in vivo. This evidence concerns the gene KRAS and cancer.